Treatment failure is still a problem for many individuals with HIV. In Europe alone, over 10,000 individuals with HIV are classed as "heavily treatment experienced"1 – but what does this really mean?

Professor Chloe Orkin and her colleagues Pedro Cahn, Antonella Castagna, Brinda Emu, Richard Harrigan, Dan Kuritzkes, Mark Nelson and Jonathan Schapiro met in December 2020 and again in 2021. Their discussions have been published in HIV Medicine (access the article below) and identify the unmet needs of individuals with HIV who are in need of further treatment options, broaden the definition of heavily treatment experienced people, and clarify the use of newer agents, with an emphasis on the utilization of entry inhibitors in this population.

This programme has been submitted for accreditation to the European Union of Medical Specialists (UEMS). User engagement with the site is being tracked, IMP will contact users with further details regarding accreditation.

Podcast 8m
Entry inhibitors and the impetus to change HIV treatment

Author: Mark Nelson

Animation 3m 59s
Opening the door on entry inhibitors in HIV

Author: Brinda Emu

Slide audio 11m 14s
Redefining the use of entry inhibitors in heavily treatment experienced and treatment-limited individuals living with HIV

Author: Chloe Orkin

Expert viewpoint 6m 10s
When should we be using entry inhibitors?

Author: Daniel Kuritzkes

Manuscript 30m
Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment-limited individuals

Author: Chloe Orkin, Pedro Cahn, Antonella Castagna et al

Slide audio 10m 49s
Matching the entry inhibitor to the individual

Author: Mark Nelson

Expert viewpoint 7m
Who should be getting entry inhibitors: a practical guide

Author: Daniel Kuritzkes

Program learning objectives

Identify individuals with HIV who have limited treatment options and describe their needs

Describe the different mechanisms of action of existing and novel entry inhibitors

Understand the impact different HIV entry inhibitors have on immune recovery

Describe and manage toxicities associated with HIV entry inhibitors

Register for free today to open the door on entry inhibitors and learn more about their important role in the treatment of people living with HIV.

  1. Pelchen-Matthews A, et al. Poster TUPEB222. 10th IAS Conference on HIV Science; July 21-24; Mexico City, Mexico 2019.